Genetically engineered NK cells with both tumour-specific chimeric antigen receptor (CAR) and induced CXCR4 chemokine expression can improve immunotherapy in solid tumours, partially by increasing tumour infiltration of NK cells [150]. The gene discussed is CXCR4; the disease is neoplasm.